Store
IVD Test Procedure Volumes, 7th Edition (2025-2030)
Publication Date: October 17, 2025
Tags: Blood Banking, Cardiovascular Disease, Clinical Chemistry, Coagulation, Cytology, Diagnostics, Diagnostics Market Research, Drug Testing, Fertility, Glucose, HbA1c, Hematology, Histology, Histology and Cytology, Immunoassay, In Vitro Diagnostics (IVD), Infectious Diseases, Mass Spectrometry, Microbiology, Molecular, Molecular Diagnostics, Oncology and Cancer, POC, Point-of-Care (POC) Diagnostics, Point-of-Care (POC) Testing, Pregnancy
Pages: 275
SKU: 25-025KA
The global in vitro diagnostics (IVD) market continues to expand in 2025, driven by powerful innovations in next-generation sequencing (NGS), microfluidics, and precision medicine that are transforming diagnostics into a more personalized, patient-centric field. IVD Test Procedure Volumes, 7th Edition (2025-2030) provides a comprehensive, data-driven analysis of global test volume trends, serving as a critical companion to Kalorama Information’s flagship publication, The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 18th Edition (2025–2030).
Quantifying the Global Testing Landscape
This report delivers an in-depth examination of IVD procedures across major testing categories—including molecular diagnostics, clinical chemistry, immunoassays, hematology, coagulation, microbiology, blood banking, and histology/cytology. It quantifies the number of tests performed, the average cost per procedure, and regional variations across key markets worldwide. With forecasts extending through 2030, the study offers essential insight into test utilization trends, cost dynamics, and evolving regional testing patterns that are shaping the global diagnostics landscape.
Technological Advancements Reshaping Diagnostics
As the IVD industry evolves beyond pandemic-driven demand, new paradigms in self-testing, home-based diagnostics, and point-of-care (POC) solutions are accelerating accessibility and reshaping healthcare delivery. Meanwhile, growth in molecular and cancer diagnostics underscores the sector’s pivot toward early detection and non-invasive monitoring through liquid biopsy and genomic testing. These advancements align with the global push toward precision medicine—but also introduce new challenges related to cost, regulation, and equitable access.
Navigating Economic and Regulatory Pressures
This report contextualizes these market drivers within a rapidly changing regulatory and economic environment. With rising scrutiny under the EU’s IVDR and FDA’s evolving frameworks, manufacturers must navigate complex approval pathways while addressing payer pressures that impact reimbursement and adoption. The balance between technological advancement, affordability, and scalability will define the next stage of IVD growth.
Methodology and Strategic Value
Drawing on Kalorama’s proprietary methodologies, this study presents accurate, transparent, and actionable estimates of IVD procedure volumes and revenues—empowering executives, strategists, and investors to benchmark performance, identify growth opportunities, and align product portfolios with emerging diagnostic trends.
An Essential Resource for IVD Decision-Makers
For organizations seeking to understand where the IVD market is headed—and how procedural demand will drive innovation, investment, and access over the next five years—IVD Test Procedure Volumes, 7th Edition (2025-2030) is an indispensable resource for strategic decision-making.
Chapter One: Executive Summary
IVD Procedure Volume Estimate and Forecast
- Figure 1-1: Global IVD Procedure Volumes, 2025 and 2030 (in millions # volume)
Scope & Methodology
Chapter Two: Introduction
Scope
Overview
Industry Trends
- Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2025-2030 (in millions # volume; $ million)
Demographic Trends
Global Population and Aging
- Figure 2-1: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
- Figure 2-2: Global Population Distribution, 2022
- Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050 [Australia, Brazil, Canada, China, China (Hong Kong SAR), France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, Singapore, South Africa, Spain, Turkey, United Kingdom, United States, World]
Workforce Reduction
- Table 2-3: WHO Model List of Essential In Vitro Diagnostics (EDL)
Increase in Chronic Diseases
- Figure 2-3: Leading Causes of Death Globally, 2021* (number of deaths in millions)
Personalized Medicine
High-Consequence Disease Threats
- Table 2-4: Selected Companies Marketing Products Addressing High-Consequence Infectious Disease Threats
Tickborne Diseases (TBDs)
Zika
Chagas
IVD Vendors Active in Chagas Diagnostics
Dengue
Ebola
Chikungunya
Middle East Respiratory Syndrome-Coronavirus (MERS-CoV)
Marburg
Monkeypox
Emerging and Emerged Markets
- Table 2-5: Developed/Developing Economies, UN Classification*, 2025
- Figure 2-4: Developed vs. Developing IVD Market Shares, 2025 and Projected 2030 (%)
Where Are the Best Markets?
- Table 2-6: Countries To Watch for IVD Opportunities, by Total Population and Percent Urban, 2025 [Australia, Brazil, China, France, Germany, Hungary, India, Mexico, Netherlands, Peru, Poland, Romania, Saudi Arabia, South Africa, South Korea, Sweden, Switzerland, Turkey, United Kingdom, United States]
Economic Growth and the Expanding Middle Class
Chapter Three: IVD Testing Segments
IVD Testing Trends
- Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2025-2030 (millions) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
- Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
- Table 3-3: IVD Procedural Volume excluding Blood Glucose Tests, 2025-2030 (millions) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
- Table 3-4: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
Segment Growth Projections
Point-of-Care (POC) Testing
Clinical Chemistry
Immunoassays
Mass Spectrometry (Immuno)
Molecular Assays
Hematology
Coagulation
Conventional Microbiology
Blood Grouping/Typing
Histology/Cytology
Segment Product Sales
- Table 3-5: IVD Product Sales including Blood Glucose Tests, 2025-2030 ($ million) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
- Table 3-6: IVD Product Sales including Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
- Table 3-7: IVD Product Sales excluding Blood Glucose Tests, 2025-2030 ($ million) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
- Table 3-8: IVD Product Sales excluding Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing]
Chapter Four: Global IVD Markets
General
- Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2025-2030 (millions) [Africa; Asia/Pacific (China, Japan, Other Countries & Territories); Eastern Europe; Mexico, Central, & South America; Middle East; North America (United States; Canada); Western Europe]
- Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2025-2030 (%) [Africa; Asia/Pacific (China, Japan, Other Countries & Territories); Eastern Europe; Mexico, Central, & South America; Middle East; North America (United States; Canada); Western Europe]
North America
United States
Canada
Mexico, Central, & South America
Brazil
Mexico
Other Central & South America
Argentina
Chile
Colombia
Peru
Venezuela
All Other Countries & Territories
Western Europe
France
Germany
Italy
Spain
United Kingdom
Other Western Europe
Austria
Belgium
Denmark
Finland
Greece
Ireland
Norway
Netherlands
Portugal
Sweden
Switzerland
All Other Countries & Territories
Eastern Europe
Russia
Other Eastern Europe
Czech Republic
Hungary
Poland
Romania
Ukraine
All Other Countries
Asia/Pacific
China
Japan
Other Asian Countries and Territories
Australia
Hong Kong
India
Indonesia
Malaysia
Pakistan
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
New Zealand
All Other Countries & Territories
Middle East
Turkey
Other Middle East
Iran
Iraq
Israel
Saudi Arabia
United Arab Emirates
All Other Countries
Africa
Nigeria
South Africa
All Other Countries & Territories
Chapter Five: Point-of-Care (POC) Procedures
Scope
Introduction
Point-of-Care (POC) Testing Overview
Global POC Procedure Volume by Test Type
- Table 5-1: Total POC Procedural Volume & Product Sales including blood glucose tests, 2025-2030
- Table 5-2: Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2025-20230
- Figure 5-1: Regional POC Procedure Volumes including blood glucose tests, 2025 [Europe, Japan, United States, Rest of World]
POC Self Tests
- Table 5-3: POC Self-Test Procedural Volume, by Type, 2025-2030 (millions) [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, H. pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
Traditional Blood Glucose Monitoring Activities
Continuous Blood Glucose Monitoring
Pregnancy and Fertility Testing
Coagulation Testing
Fecal Occult Blood Testing
Drugs of Abuse Testing
- pylori Testing
HIV Testing
Infectious Disease
Cholesterol Testing
POC Urinalysis Testing
Other POC Self-Testing
POC Self-Testing Product Sales
- Table 5-4: POC Self-Test Product Sales, by Type, 2025-2030 ($ million) [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
Pricing Trends
- Table 5-5: POC Self-Test $ IVD Products Per Procedure, 2025-2030 [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose, Continuous, Glucose, Self, pylori, HIV, Infectious Disease (incl. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]
POC Professional Testing
- Table 5-6: POC Professional Procedural Volume, by Type, 2025-2030 [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]
POC Professional Blood Glucose Testing Procedures
POC Professional Critical Care Testing
POC Fertility Testing
POC Professional Infectious Disease Testing
POC Professional Cardiac Marker Testing
POC Professional Cholesterol/Lipid Testing
POC Professional Coagulation Testing
POC Professional HbA1C Testing
POC Professional Hematology Testing
POC Professional Fecal Occult Blood Screening
POC Professional Drugs of Abuse Testing
POC Professional Urinalysis Testing
Other POC Professional Testing
POC IVD Product Sales
- Table 5-7: POC Professional IVD Product Sales, by Type, 2025-2030 ($ million) [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]
Pricing Trends
- Table 5-8: POC Professional $ IVD Products Per Procedure, by Type 2025-2030 [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]
Chapter Six: Clinical Chemistry Procedures
Scope
Introduction
- Table 6-1: Clinical Chemistry Procedural Volume, by Type, 2025-2030 [Blood Gas Analysis, General Chemistry, Urinalysis]
- Figure 6-1: Regional Clinical Chemistry Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
Types of Tests
General Chemistry
Enzymes
Glucose
Lipids
Proteins
Other Compounds
Blood Gases & Electrolytes
Urinalysis
Global Sales of Clinical Chemistry Products
- Table 6-2: Clinical Chemistry Product Sales, by Type, 2025-2030 ($ million) [Blood Gas Analysis, General Chemistry, Urinalysis]
Pricing Trends
- Table 6-3: Clinical Chemistry $ IVD Product Sales Per Procedure, 2025-2030 [Blood Gas Analysis, General Chemistry, Urinalysis]
Chapter Seven: Immunoassay Procedures
Scope
Introduction
Labeling Techniques
Enzyme Immunoassays
Chemiluminescent Magnetic Immunoassays (CMIAs)
Fluorescence Polarization Immunoassays (FPIAs)
Radioimmunoassays (RIAs)
- Table 7-1: Immunoassay Procedural Volume, by Type, 2025-2030 [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]
- Figure 7-1: Regional Immunoassay Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
Testing Procedures & Product Sales
- Table 7-2: Immunoassay Product Sales, by Type, 2025-2030 ($ million) [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]
Cardiac Markers
Tumor Markers
Autoimmune Conditions
Allergy Conditions
Thyroid Conditions
Proteins
Alzheimer’s Disease
Anemia
Fertility Testing
Therapeutic Drug Monitoring
Vitamin D
Diabetes/HbA1c
Drugs of Abuse
Infectious Diseases
- Table 7-3: Immunoassay Infectious Disease Procedural Volume, by Type, 2025-2030 [HAI, Hepatitis, HIV, Resp, STD, ToRCH, Other]
- Table 7-4: Immunoassay Infectious Disease Product Sales, by Type, 2025-2030 ($ million) [HAI, Hepatitis, HIV, Resp, STD, ToRCH, Other]
Instruments
Pricing Trends
- Table 7-5: Immunoassay $ Product Sales Per Procedure, by Type, 2025-2030 [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spectrometry, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]
Chapter Eight: Molecular Testing Procedures
Introduction
- Table 8-1: Molecular Assay Procedural Volume, by Type, 2025-2030 (millions) [Molecular – Other, Molecular Assays – Oncology, Molecular Blood Bank, Molecular Histology – Non Cancer, Molecular Histology – Cancer, Molecular HPV, Molecular Infectious Disease, Molecular Inherited Diseases, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) Tissue Typing, Prenatal]
- Figure 8-1: Regional Molecular Assay Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
Types of Tests
Testing Technologies
Infectious Diseases
- Table 8-2: Molecular Assay Infectious Disease Procedural Volume, by Type, 2025-2030 [COVID, GC/Chlamydia, HAI, Hepatitis, HIV, Mycobacteria/TB, Respiratory non-COVID, Other]
Blood Screening
Cancer
Transplant Matching
Thrombophilia SNPs
Inherited Diseases
Other Molecular Tests
Prenatal
Global Sales of Molecular IVD Products
- Table 8-3: Molecular Assay Product Sales, by Type, 2025-2030 ($ million) [Genetic Testing/Inherited Disease, Molecular Assays – Oncology, Molecular Blood bank, Molecular Histology – Cancer, Molecular Histology – Non Cancer, Molecular HPV, Molecular Infectious disease, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) tissue typing, Other Molecular, Prenatal]
- Table 8-4: Molecular Assay Infectious Disease Product Sales, by Type, 2025-2030 ($ million) [COVID, GC/Chlamydia, HAI, Hepatitis, HIV, Mycobacteria/TB, Respiratory non-COVID, Other]
Pricing Trends
- Table 8-5: Molecular Assays $ Products per Procedure, by Type, 2025-2030 [Molecular Assays – Oncology, Molecular Blood bank, Molecular Histology – cancer, Molecular Histology – non cancer, Molecular HPV, Molecular Infectious disease, Molecular Inherited Diseases, Molecular Other, Molecular PT/INR (thrombophilia SNP tests), Molecular Transplant Testing (HLA) tissue typing, Prenatal]
Chapter Nine: Laboratory-Based Hematology Procedures
Scope
Introduction
- Table 9-1: Laboratory-Based Hematology Procedural Volume, by Type, 2025-2030 [Complete Blood Count, Other Hematology Tests]
- Figure 9-1: Regional Laboratory-Based Hematology Procedure Volumes, 2025 [Asia Pacific, Europe, United States, Rest of World]
Types of Tests
Global Sales of Hematology Products
- Table 9-2: Laboratory-Based Hematology Product Sales, by Type, 2025-2030 ($ million) [Complete Blood Count, Other Hematology Tests]
Pricing Trends
- Table 9-3: Hematology $ Product Sales Per Procedure, by Type, 2025-2030 [Complete Blood Count, Other Hematology Tests]
Chapter Ten: Coagulation Testing Procedures
Introduction
- Table 10-1: Coagulation Procedural Volume, 2025-2030 [D-dimer, PT/INR]
- Figure 10-1: US/ROW Coagulation Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
Types of Tests
Global Sales of Coagulation Products
- Table 10-2: Coagulation Product Sales, 2025-2030 ($ million) (D-dimer, PT/INR)
Pricing Trends
- Table 10-3: Coagulation $ Products per Procedure, 2025-2030 [D-dimer, PT/INR]
Chapter Eleven: Microbiology Procedures
Scope
Introduction
- Table 11-1: Conventional Microbiology Procedural Volume, by Type, 2025-2030 [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]
Types of Tests
ID/AST Automated Panels & Reagents
Manual Panels & Reagents
Blood Culture
Chromogenic Media
Rapid Microbiological Tests
Mass Spectrometry
Global Sales of Conventional IVD Microbiology Products
ID/AST Panels & Reagents
Blood Culture
Chromogenic Media
Rapid Microbiological Tests
Mass Spectrometry
- Table 11-2: Conventional Microbiology Product Sales, by Type, 2025-2030 ($ million) [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]
Pricing Trends
- Table 11-3: Conventional Microbiology $ Product Sales Per Procedures, by Type, 2025-2030 [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]
Chapter Twelve: Blood Grouping/Typing Procedures
Introduction
- Table 12-1: Blood Grouping/Typing Procedure Volumes, 2025-2030
- Figure 12-1: Regional Blood Grouping/Typing Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
Types of Tests
Blood Grouping/Typing Product Sales
- Table 12-2: Blood Grouping/Typing Product Sales, 2025-2030 ($ million)
Pricing Trends
- Table 12-3: Blood Grouping/Matching $ Product Sales/Procedure, 2025-2030
Chapter Thirteen: Histology/Cytology Procedures
Scope
Introduction
- Table 13-1: Histology/Cytology Procedural Volume, by Type, 2025-2030 [CTCs, Flow Cytometry, Immunohistochemistry, In situ Hybridization, Pap Tests, Traditional non-Pap Stains]
- Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2025 [Asia Pacific, Europe, North America, Rest of World]
Types of Tests
Immunohistochemistry Tests
In Situ Hybridization Tests
Pap Tests
Traditional Non-Pap Stains
Circulating Tumor Cells
Flow Cytometry
Histology/Cytology IVD Product Sales
- Table 13-2: Histology/Cytology Product Sales, by Type, 2025-2030 ($ million) [CTCs, Flow Cytometry, Immunohistochemistry, In situ Hybridization, Pap Tests, Traditional non-Pap Stains]
Pricing Trends
- Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2025-2030
Chapter Fourteen: Company Profiles
Introduction
- Table 14-1: Revenues of Selected Top 20 IVD Companies, 2024 and estimated 2025 ($ million) [Abbott Diagnostics, Agilent, Becton Dickinson, bioMérieux, Bio-Rad Laboratories, Bruker – CALID, Danaher, Dexcom, Diasorin, Exact Sciences, Hologic, Illumina, Natera, QuidelOrtho, Revvity, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific, Werfen]
Abbott Diagnostics
Recent Revenue History
- Table 14-2: Abbott Diagnostic Revenues, 2022-2024 ($ million)
- Table 14-3: Abbott Diagnostic Revenues, by Segment, 2022-2024 ($ million, estimated)
Agilent Technologies
Recent Revenue History
- Table 14-4: Agilent Revenues, 2022-2024 (million $)
Becton, Dickinson and Company (BD)
Recent Revenue History
- Table 14-5: BD Diagnostic Revenues, 2022-2024 (million $) FYE Sept 30
bioMérieux Inc.
Recent Revenue History
- Table 14-6: bioMérieux IVD Revenues, 2022-2024 (€ million)
Bio-Rad Laboratories, Inc.
Recent Revenue History
- Table 14-7: Bio-Rad Diagnostics Revenues, 2022-2024 ($ million)
Danaher Corporation
Recent Revenue History
- Table 14-8: Danaher Global IVD Diagnostic Sales, 2022-2024 ($ million)
Dexcom
Recent Revenue History
- Table 14-9: Dexcom IVD Diagnostic Sales, 2022-2024 ($ million)
Diasorin
Recent Revenue History
- Table 14-10: Diasorin Revenues, 2022-2024 (million €)
Exact Sciences
Recent Revenue History
- Table 14-11: Exact Sciences Revenues, 2022-2024 ($ million)
Hologic, Inc.
Recent Revenue History
- Table 14-12: Hologic Revenues, 2022-2024 ($ million)
Illumina
Recent Revenue History
- Table 14-13: Illumina Diagnostics Revenues, 2022-2024 ($ million)
Recent Revenue History
- Table 14-14: Mindray Revenue History, 2022-2024 (billion CNY)
Natera
Recent Revenue History
- Table 14-15: Natera Revenue History, 2022-2024 ($ million)
QuidelOrtho Corporation
Recent Revenue History
- Table 14-16: QuidelOrtho Revenue History, 2022-2024 ($ million)
- Table 14-17: QuidelOrtho Diagnostic Revenues, by Segment, 2022-2024 ($ million, estimated)
Revvity
- Table 14-18: Revvity Revenue History, 2022-2024 ($ million, estimated)
Roche Diagnostics
Recent Revenue History
- Table 14-19: Roche Diagnostics IVD Revenues, 2022-2024 (CHF million)
- Table 14-20: Roche Diagnostic Revenues, by Segment, 2023-2024 (CHF million)
Siemens Healthineers (Siemens)
Recent Revenue History
- Table 14-21: Siemens Healthineers IVD Revenues, 2022-2024 (€ million)
Sysmex Corporation
Recent Revenue History
- Table 14-22: Sysmex IVD Revenues, 2022-2024 (FY March 31) (billions of yen)
- Table 14-23: Sysmex Diagnostic Revenues, by Segment, 2022-2024 (billions of yen)
Thermo Fisher Scientific Inc.
Recent Revenue History
- Table 14-24: Thermo Fischer IVD Revenues, 2022-2024 ($ million)
Werfen
Recent Revenue History
- Table 14-25: Werfen IVD Revenues, 2022-2024 (€ billion)
Related products
COVID-19 Testing Markets, 2023
May 18, 2023
As the COVID-19 pandemic evolves into an endemic phase, the landscape of COVID-19 testing is changing rapidly. Kalorama Information’s COVID-19 Testing Markets, 2023 report provides crucial insights into this shifting market, answering key questions and providing valuable market sizing and estimates.
Key Insights Provided:
- Market impacts and trends in the evolving COVID-19 testing…
Price range: $4,000.00 through $6,000.00
Histology and Cytology IVD Market Update, 2024
May 21, 2024
Histology and cytology have long been essential components of pathological laboratories, offering critical insights into cells, tissues, and organs. Through histopathological examinations, a variety of diseases, including cancer, can be accurately diagnosed. Physicians rely heavily on pathological information to determine treatment plans and prognoses.
Histology and Cytology IVD Market Update, 2024 provides an in-depth competitive analysis…
Price range: $5,000.00 through $7,875.00
The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition
March 7, 2024
Explore the cutting-edge world of molecular point-of-care (mPOC) diagnostic solutions with our latest report, offering a detailed analysis of the market and future growth potential from 2023-2028. mPOC technology revolutionizes diagnostic capabilities, providing enhanced sensitivity and specificity compared to traditional near-patient tests. These solutions are instrumental in critical care units, physician offices, outpatient clinics,…
Price range: $5,000.00 through $7,875.00
![30-Country In Vitro Diagnostic (IVD) Market Atlas [October 2023 Update]](https://www.scienceandmedicinegroup.com/wp-content/uploads/2025/06/Kalorama-1.svg)